Bio-Rad Laboratories Inc (BIO)vsDexCom Inc (DXCM)
BIO
Bio-Rad Laboratories Inc
$369.32
+0.15%
HEALTHCARE · Cap: $10.17B
DXCM
DexCom Inc
$83.03
-1.75%
HEALTHCARE · Cap: $31.90B
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 92% more annual revenue ($4.97B vs $2.59B). DXCM leads profitability with a 20.1% profit margin vs 8.6%. BIO appears more attractively valued with a PEG of 1.19. DXCM earns a higher WallStSmart Score of 74/100 (B).
BIO
Buy55
out of 100
Grade: C-
DXCM
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-46.5%
Fair Value
$200.53
Current Price
$369.32
$168.79 premium
Intrinsic value data unavailable for DXCM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Every $100 of equity generates 38 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Areas to Watch
ROE of 2.5% — below average capital efficiency
Weak financial health signals
Premium valuation, high expectations priced in
Revenue declined 0.1%
Premium valuation, high expectations priced in
Trading at 11.9x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : BIO
The strongest argument for BIO centers on Price/Book, Altman Z-Score, Debt/Equity. PEG of 1.19 suggests the stock is reasonably priced for its growth.
Bull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bear Case : BIO
The primary concerns for BIO are Return on Equity, Piotroski F-Score, P/E Ratio. A P/E of 46.2x leaves little room for execution misses.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Key Dynamics to Monitor
BIO profiles as a value stock while DXCM is a mature play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.42 — expect wider price swings.
DXCM is growing revenue faster at 13.1% — sustainability is the question.
DXCM generates stronger free cash flow (185M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (74/100 vs 55/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bio-Rad Laboratories Inc
HEALTHCARE · MEDICAL DEVICES · USA
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.
Visit Website →DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?